share_log

Wedbush Reiterates Outperform on Cullinan Therapeutics, Maintains $36 Price Target

Benzinga ·  Sep 18 20:23  · Ratings

Wedbush analyst Robert Driscoll reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and maintains $36 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment